BY13

BY13 : Degrader (PROTAC) of NCOA3

Structure

SERP Rating

In Cells

(1 ratings)

In Model Organisms

(1 ratings)

note: The Chemical Probes Portal only endorses compounds as chemical probes for use as specific and selective modulators of the proposed target if they receive three or more (3-4) stars.

Probe BY13 is in the process of SERP review.

Please continue to check back for new reviews and commentary.

Information

NCOA3

Degrader (PROTAC)

up to 1 uM

In Vitro Validations

No in Vitro Validations

In Cell Validations

In Vivo Data

Off-Target Selectivity Assesments

Potency assay, off target (cells): Global quantitative proteomics screen was conducted in LCC2 cells after 36 h of treatment with BY13. Although WB analysis has confirmed that compound BY13 could significantly degrade SRC-3, diaPASEF-based quantitative proteomics analysis revealed only moderate degradation of SRC-3 (−log2FC = −0.25).

Probe Selectivity in Cell:

Both ERα and CDK4 protein levels were profoundly downregulated by BY13. BY13 containing pomalidomide moiety showed no appreciable off-target degradation activity against ubiquitously recognized CRBN substrates (e.g., CK1α and GSPT1). Other CRBN neo-substrates such as IKZF1, IKZF2, and IKZF3 were not detected in breast cancer cells before and after BY13 treatment.

I have extra information to add

SERP ratings and comments

SERP Ratings

In Cell Rating

In Model Organisms

SERP Comments:

This is a PROTAC (proteolysis-targeting chimera) that has high selectivity for the estrogen receptor signaling pathway and is an effective SRC-3 degrader, which exhibits significant inhibitory activity against ER breast cancer. It inhibits the proliferation of MCF-7 cells with low nanomolar IC50 values.

(last updated: 23 Feb 2026 )